CVCapsoVision, Inc
Is CapsoVision struggling financially?
Yes, by its own account. CapsoVision told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
0/100
Critical
- Sector
- Biotech/Pharma
- Market cap
- $301.3M
- Source filing
- 10-Q 14 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
Not estimable
The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.
What it reported
Cash burned over the last 12 months
$23.0M
What CapsoVision told the SEC
…used in operating activities of $ 6,066 . The Company, having evaluated the extant facts and circumstances, concluded that the facts and circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date of issuance of these financial statements. While the Company raised approximately $ 14 million in gross proceeds resulting from subsequent Private…
CapsoVision, Inc, Form 10-Q, filed 14 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 2088.7% share-count increase The company issued stock. Each share now owns 95.4% less of the business than a year ago, before any change in the price.
Other Biotech/Pharma companies that filed the doubt
- IMNN Imunon $9.2M
- GRML Greenland Mines $32.2M
- CNXU Conexeu Sciences $237.9M
- IBO Impact BioMedical $51.8M
- KALA KALA BIO $15.9M
- LMRI Lumexa Imaging Holdings $1.2B